Study of Sevelamer effect on nephropathic patients

Phase 2

• Conditions: Diabetic nephropathy.; Type 2 diabetes mellitus with diabetic nephropathy; E11.21

• Registration Number: IRCT20191111045401N1
• Lead Sponsor: Shahre-kord University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 March 2020

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 48

Inclusion Criteria

Age over 18 years.
Informed patient satisfaction
diabetic nephropathy

Exclusion Criteria

Recently received treatment of hyperphosphatemia
Have hypophosphatemia or hypercalcemia
Pregnancy
Known liver disease or active peptic ulcer5
Carbamazepine consumption

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
BS. Timepoint: Before the beginning of study and two month after using the sevelamer and placebo. Method of measurement: Biochemical assay using BTand optical absorption teqniqus and centrifugation of serum by sampler.;Inflamatory factors(ESR,CRP). Timepoint: Before the beginning of study and two month after using the sevelamer and placebo. Method of measurement: quantitative qualitative.;HBA1C. Timepoint: Before the beginning of study and two month after using the sevelamer and placebo. Method of measurement: Using the optical absorption method, we first use a kind of solution that binds to the glycosylated hemoglobin and produced color then we should mesure colored HB.;Inflamatory factor(ICAM,VCAM). Timepoint: Before the beginning of study and two month after using the sevelamer and placebo. Method of measurement: Elisa(measurement the serum level of Antibody).

Secondary Outcome Measures

Name	Time	Method
Degree of systemic inflamation. Timepoint: Befour study and two month after using the drugs. Method of measurement: Quantitative rate of Inflamatory Factor.